Drug Safety Conference London 2018
SMi Group are pleased to announce their 5th Drug Safety conference, taking place on the 11th – 12th June 2018 in London, UK.
For drugs anywhere, it’s the safety in patients which is a huge issue constantly under surveillance, irrespective of where the drug is in its pipeline.
The Global Pharmaceutical Market currently has a market value of $1057 billion. If a drug is found to be unsafe, causing serious side effects, it can have a huge knock on effect on revenue, causing huge losses to pharmaceutical companies manufacturing the drug.
Therefore, Drug Safety 2018 aims to discuss the latest findings and current thinking on pharmacovigilance. Importantly, it will address the newest regulatory updates and interpretations of them, including the impact of the vital and much awaited Clinical Trial Regulations.
Registration is now live for you to join SMi’s growing community in drug safety. Download the agenda to take a look at some of our confirmed speakers and save up to £400 with our special early-bird rates available. Secure your place online at: http://www.drugsafetyconference.co.uk/phev
Network & Benefit From Industry Experts:
Chair for 2018:
– Susan Welsh, Chief Safety Officer, CSL Behring
– David Lewis, Senior Adviser Pharmacovigilance, CMO Patient Safety, Novartis
– Peter De Veene, Senior Vice President and Head Global Drug Safety and QPPV, Grünenthal
– Simon Ashworth, VP EU QPPV, EU Head Compliance and Marketed Products and Head PV Affiliate Relations, Takeda
– Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, MHRA
– John Solomon, Head of Pharmacovigilance-UK & Ireland, Sanofi
– Bjarke Naver, Head of Pharmacovigilance Science, LEO Pharma
– Sue Rees, EU QPPV, Executive Director, Global Safety, Amgen
– Jackie Roberts, Executive Director Regulatory, Pharmacovigilance and Medical UK/IE/Malta and MENA, Accord Healthcare
– Philip Eichorn, Senior Director, Worldwide Safety and Regulatory, Pfizer
– Rawya Al Kredly, Director of Medical Affairs Department, Gulf Pharmaceutical Industries (Julphar)
– Bert van Leeuwen, Deputy QPPV, Astellas
– Kashif Sheikh, Safety Surveillance Specialist, Novo Nordisk
Featured Highlights this June:
– MHRA spotlight presentation on the future of Clinical Trial Regulations
– Hear first experiences with the new Eudravigilence system
– Gain insight into how competitors are reporting adverse effects under the new legislation and system
– Discuss risk-minimisation and signal detection strategies with industry-thought leaders
– Evaluate the benefits and pitfalls of patient involvement and patient support programs
PLUS… An Interactive Half-Day Post-Conference Workshop:
Workshop: PASS: Evaluation of Risk Minimisation
Workshop Leader: Nawab Qizilbash, Head, OXON Epidemiology and Honorary Associate Professor, London School of Hygiene & Tropical Medicine
Brief Overview: Learn about risk minimisation in Europe: its implementation, evaluation and PRAC expectations.
Download the complete brochure online for all sessions and speaker line-up: http://www.drugsafetyconference.co.uk/phev